Agilent Technologies, Inc. (0HAV.L)
USD 101.8
(-8.59%)
USD 101.8
(-8.59%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.03 Billion USD | -0.67% |
| 2022 | 1.03 Billion USD | 25.06% |
| 2021 | 830 Million USD | 15.28% |
| 2020 | 720 Million USD | 6.04% |
| 2019 | 679 Million USD | 6.43% |
| 2018 | 638 Million USD | 10.96% |
| 2017 | 575 Million USD | 7.88% |
| 2016 | 533 Million USD | -1.48% |
| 2015 | 541 Million USD | -49.53% |
| 2014 | 1.07 Billion USD | 0.56% |
| 2013 | 1.06 Billion USD | 5.13% |
| 2012 | 1.01 Billion USD | 12.92% |
| 2011 | 898 Million USD | 25.42% |
| 2010 | 716 Million USD | 29.71% |
| 2009 | 552 Million USD | -14.55% |
| 2008 | 646 Million USD | 0.47% |
| 2007 | 643 Million USD | 2.55% |
| 2006 | 627 Million USD | -13.16% |
| 2005 | 722 Million USD | -29.63% |
| 2004 | 1.02 Billion USD | 3.12% |
| 2003 | 995 Million USD | -15.96% |
| 2002 | 1.18 Billion USD | -20.59% |
| 2001 | 1.49 Billion USD | -19.54% |
| 2000 | 1.85 Billion USD | 23.62% |
| 1999 | 1.49 Billion USD | 0.94% |
| 1998 | 1.48 Billion USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 1 Billion USD | -3.19% |
| 2024 Q1 | 1.03 Billion USD | 0.19% |
| 2024 Q3 | 978 Million USD | -2.2% |
| 2023 Q2 | 1.1 Billion USD | -0.72% |
| 2023 Q4 | 1.03 Billion USD | -3.82% |
| 2023 Q3 | 1.07 Billion USD | -2.81% |
| 2023 Q1 | 1.11 Billion USD | 7.03% |
| 2023 FY | 1.03 Billion USD | -0.67% |
| 2022 Q3 | 1.01 Billion USD | 7.79% |
| 2022 Q4 | 1.03 Billion USD | 2.77% |
| 2022 FY | 1.03 Billion USD | 25.06% |
| 2022 Q1 | 879 Million USD | 5.9% |
| 2022 Q2 | 937 Million USD | 6.6% |
| 2021 Q2 | 791 Million USD | 4.77% |
| 2021 Q1 | 755 Million USD | 4.86% |
| 2021 FY | 830 Million USD | 15.28% |
| 2021 Q4 | 830 Million USD | 1.47% |
| 2021 Q3 | 818 Million USD | 3.41% |
| 2020 Q1 | 706 Million USD | 3.98% |
| 2020 Q2 | 750 Million USD | 6.23% |
| 2020 Q3 | 746 Million USD | -0.53% |
| 2020 Q4 | 720 Million USD | -3.49% |
| 2020 FY | 720 Million USD | 6.04% |
| 2019 FY | 679 Million USD | 6.43% |
| 2019 Q4 | 679 Million USD | 2.88% |
| 2019 Q1 | 653 Million USD | 2.35% |
| 2019 Q2 | 657 Million USD | 0.61% |
| 2019 Q3 | 660 Million USD | 0.46% |
| 2018 Q3 | 623 Million USD | 4.88% |
| 2018 FY | 638 Million USD | 10.96% |
| 2018 Q1 | 608 Million USD | 5.74% |
| 2018 Q2 | 594 Million USD | -2.3% |
| 2018 Q4 | 638 Million USD | 2.41% |
| 2017 FY | 575 Million USD | 7.88% |
| 2017 Q3 | 566 Million USD | 3.28% |
| 2017 Q2 | 548 Million USD | -0.54% |
| 2017 Q1 | 551 Million USD | 3.38% |
| 2017 Q4 | 575 Million USD | 1.59% |
| 2016 Q2 | 555 Million USD | 0.18% |
| 2016 FY | 533 Million USD | -1.48% |
| 2016 Q1 | 554 Million USD | 2.4% |
| 2016 Q4 | 533 Million USD | -1.84% |
| 2016 Q3 | 543 Million USD | -2.16% |
| 2015 Q3 | 545 Million USD | -1.98% |
| 2015 Q1 | 560 Million USD | -47.76% |
| 2015 Q4 | 541 Million USD | -0.73% |
| 2015 FY | 541 Million USD | -49.53% |
| 2015 Q2 | 556 Million USD | -0.71% |
| 2014 FY | 1.07 Billion USD | 0.56% |
| 2014 Q1 | 1.08 Billion USD | 2.06% |
| 2014 Q4 | 1.07 Billion USD | -2.46% |
| 2014 Q3 | 1.09 Billion USD | -0.09% |
| 2014 Q2 | 1.1 Billion USD | 1.1% |
| 2013 FY | 1.06 Billion USD | 5.13% |
| 2013 Q4 | 1.06 Billion USD | 1.14% |
| 2013 Q1 | 1.04 Billion USD | 2.56% |
| 2013 Q2 | 1.04 Billion USD | 0.19% |
| 2013 Q3 | 1.05 Billion USD | 1.15% |
| 2012 Q2 | 947 Million USD | 1.07% |
| 2012 FY | 1.01 Billion USD | 12.92% |
| 2012 Q4 | 1.01 Billion USD | -2.12% |
| 2012 Q3 | 1.03 Billion USD | 9.4% |
| 2012 Q1 | 937 Million USD | 4.34% |
| 2011 FY | 898 Million USD | 25.42% |
| 2011 Q4 | 898 Million USD | 0.11% |
| 2011 Q3 | 897 Million USD | 5.16% |
| 2011 Q2 | 853 Million USD | 7.03% |
| 2011 Q1 | 797 Million USD | 11.31% |
| 2010 FY | 716 Million USD | 29.71% |
| 2010 Q3 | 688 Million USD | 26.01% |
| 2010 Q2 | 546 Million USD | -0.36% |
| 2010 Q1 | 548 Million USD | -0.72% |
| 2010 Q4 | 716 Million USD | 4.07% |
| 2009 Q2 | 608 Million USD | -7.18% |
| 2009 Q1 | 655 Million USD | 1.39% |
| 2009 FY | 552 Million USD | -14.55% |
| 2009 Q3 | 571 Million USD | -6.09% |
| 2009 Q4 | 552 Million USD | -3.33% |
| 2008 Q3 | 674 Million USD | 0.0% |
| 2008 Q2 | 674 Million USD | 0.0% |
| 2008 FY | 646 Million USD | 0.47% |
| 2008 Q4 | 646 Million USD | -4.15% |
| 2008 Q1 | 674 Million USD | 4.82% |
| 2007 Q2 | 650 Million USD | 0.31% |
| 2007 Q4 | 643 Million USD | -4.6% |
| 2007 FY | 643 Million USD | 2.55% |
| 2007 Q1 | 648 Million USD | 3.35% |
| 2007 Q3 | 674 Million USD | 3.69% |
| 2006 Q1 | 740 Million USD | 2.49% |
| 2006 FY | 627 Million USD | -13.16% |
| 2006 Q4 | 627 Million USD | -11.06% |
| 2006 Q3 | 705 Million USD | -1.12% |
| 2006 Q2 | 713 Million USD | -3.65% |
| 2005 Q3 | 936 Million USD | -2.3% |
| 2005 Q4 | 722 Million USD | -22.86% |
| 2005 Q1 | 1.03 Billion USD | 1.07% |
| 2005 Q2 | 958 Million USD | -7.62% |
| 2005 FY | 722 Million USD | -29.63% |
| 2004 Q2 | 1.05 Billion USD | -0.57% |
| 2004 Q1 | 1.05 Billion USD | 6.13% |
| 2004 FY | 1.02 Billion USD | 3.12% |
| 2004 Q3 | 1.06 Billion USD | 1.05% |
| 2004 Q4 | 1.02 Billion USD | -3.3% |
| 2003 FY | 995 Million USD | -15.96% |
| 2003 Q4 | 995 Million USD | -5.33% |
| 2003 Q3 | 1.05 Billion USD | -7.07% |
| 2003 Q1 | 1.16 Billion USD | -1.52% |
| 2003 Q2 | 1.13 Billion USD | -3.0% |
| 2002 Q2 | 1.3 Billion USD | -5.43% |
| 2002 Q3 | 1.3 Billion USD | -0.46% |
| 2002 Q4 | 1.18 Billion USD | -8.99% |
| 2002 FY | 1.18 Billion USD | -20.59% |
| 2002 Q1 | 1.38 Billion USD | -7.31% |
| 2001 Q4 | 1.49 Billion USD | -12.5% |
| 2001 Q3 | 1.7 Billion USD | -4.86% |
| 2001 Q2 | 1.79 Billion USD | -15.88% |
| 2001 FY | 1.49 Billion USD | -19.54% |
| 2001 Q1 | 2.12 Billion USD | 14.89% |
| 2000 Q1 | 1.56 Billion USD | 4.54% |
| 2000 Q2 | 1.62 Billion USD | 3.51% |
| 2000 Q3 | 1.76 Billion USD | 8.63% |
| 2000 FY | 1.85 Billion USD | 23.62% |
| 2000 Q4 | 1.85 Billion USD | 5.16% |
| 1999 Q4 | 1.49 Billion USD | 0.0% |
| 1999 FY | 1.49 Billion USD | 0.94% |
| 1998 FY | 1.48 Billion USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -8474.518% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -5304.697% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -1627.084% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -10522.295% |
| bluebird bio, Inc. | 22.91 Million USD | -4398.451% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -36447.324% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -167.192% |
| Myriad Genetics, Inc. | 20.1 Million USD | -5029.353% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -2591.906% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -1231.904% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 87.608% |
| Waters Corporation | 516.23 Million USD | -99.715% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 79.737% |
| Biogen Inc. | 2.52 Billion USD | 59.207% |
| Nektar Therapeutics | 16.1 Million USD | -6303.329% |
| Perrigo Company plc | 1.14 Billion USD | 9.633% |
| Dynavax Technologies Corporation | 53.29 Million USD | -1834.697% |
| Illumina, Inc. | 587 Million USD | -75.639% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -9840.224% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -2348.35% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 6.881% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -9274.432% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 60.047% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -1471.096% |
| FibroGen, Inc. | 41.56 Million USD | -2380.452% |
| OPKO Health, Inc. | 65.69 Million USD | -1469.326% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -1056.53% |
| Exelixis, Inc. | 17.32 Million USD | -5851.625% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 59.789% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -6712.025% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 42284.943% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | -39.551% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -3527.089% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -219.334% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -13237.646% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -707.987% |
| Blueprint Medicines Corporation | 21.22 Million USD | -4757.937% |
| Insmed Incorporated | 83.24 Million USD | -1138.468% |
| TG Therapeutics, Inc. | 39.82 Million USD | -2488.956% |
| Incyte Corporation | 62.97 Million USD | -1537.236% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -213.469% |